Pirodavir, ≥98%

??【編號】：126501

??【產(chǎn)品名稱】：Pirodavir, ≥98%

??【規(guī)格】：5MG

??【用途】：

　　Pirodavir, ≥98%

　　Product Name： Pirodavir

　　CAS號：124436-59-5

　　分子式：C21H27N3O3

　　分子量：369.46

　　貯存：儲存溫度-20°C

　　可溶性： 25°C： DMSO 67 mg/mL; Water <1 mg/mL; Ethanol 7 mg/mL

　　生化和生理學機理：

　　Description： IC50 Value： Pirodavir inhibits 80 percentage of viruses at 0.064 micrograms/ml(EC80)[2]. pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. Susceptibility to hydrolysis precluded its use as an oral agent [1]. in vitro： R-77975's predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC80) at concentrations above 32 micrograms/ml, pirodavir inhibits the same percentage of viruses at 0.064 micrograms/ml. Pirodavir is also effective in inhibiting 16 enteroviruses, with an EC80 of 1.3 micrograms/ml. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication [2]. in vivo： Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times daily for 5 days. In people with laboratory-documented rhinovirus colds (53 in the pirodavir group, 55 in the placebo group), no significant differences in the resolution of respiratory symptoms were apparent between the groups. The median duration of illness was 7 days in each group. Similarly, scores for individual symptoms found no differences in favor of pirodavir during or after treatment [3]. Clinical trial： N/A

上一篇：PF-8380, ≥98%		下一篇：帕立骨化醇，≥99％

Pirodavir, ≥98%

產(chǎn)品明細

熱銷產(chǎn)品 新品上架

產(chǎn)品推薦 相關產(chǎn)品

Pirodavir, ≥98%

產(chǎn)品明細

熱銷產(chǎn)品 新品上架

產(chǎn)品推薦 相關產(chǎn)品

　　Pirodavir, ≥98%

熱銷產(chǎn)品新品上架

產(chǎn)品推薦相關產(chǎn)品